EnteroTrack Developing and Commercializing Non-Invasive Device To Monitor Gastrointestinal Tract Inflammation

EnteroTrack Developing and Commercializing Non-Invasive Device To Monitor Gastrointestinal Tract Inflammation
shutterstock_204635974EnteroTrack, LLC and the University of Colorado (CU) recently signed an exclusive agreement that will allow the company to develop and market a new monitoring device for gastrointestinal tract inflammation. The new technology could enhance current diagnostic and treatment approaches for a variety of GI diseases, including IBD, where inflammation is an issue. It is often difficult to diagnose inflammatory conditions of the gastrointestinal tract because blood tests and radio-imaging are not able to define the original cause of the inflammation itself. Thus, patients suffering with conditions such eosinophilic esophagitis, severe gastroesophageal reflux, eosinophilic gastroenteritis, food allergic enteropathy and inflammatory bowel disease have to be diagnosed through endoscopy, a technique that uses an instrument to visualize the esophagus and that makes possible to collect samples that can be tested. EnteroTrack is developing a capsule that allows the analysis of the esophageal content through a simple and low-cost procedure. This capsule can identify the presence of esophageal inflammation and assure that the patient is treated effect
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *